CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 228 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05318144
NCT05318144N/ACompleted

Prognostic Value of Serum Melatonin as a Biomarker for the Determination of Severe COVID-19 Infection in Pregnant Women

Nazan Yurtcu MD·observational·Posted Apr 8, 2022·Updated Apr 8, 2022

In Brief

An observational study for COVID-19 Acute Respiratory Distress Syndrome and 2 related conditions. Completed, enrolled 228 participants across 1 site.

Detailed Summary

This study aimed to investigate the prognostic value of serum melatonin as a biomarker for the determination of severe COVID-19 infection in pregnant women. Four study groups were formed, including pregnant women with a positive COVID-19 PCR test, severe symptoms, and inpatient treatment. Pregnant women who had complaints similar to COVID-19 infection or had no complaints, but had a PCR test due to the surveillance program and negative test results were included in the control group. Methods and Main Outcome measure: Laboratory values of the cases at the time of diagnosis parameters were collected. Melatonin levels decrease in pregnant women with COVID-19 symptoms, the severity of symptoms increases. In addition, patients with low melatonin levels have an increase in infection parameters and an increase in the hospital stay.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedApr 8, 2022
Enrollment StartJun 1, 2021
Primary CompletionDec 1, 2021
Study CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.2 years ago

Interventions

other